Akorn (AKRX) Upgraded by BidaskClub to Sell
Akorn (NASDAQ:AKRX) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Monday.
Several other research firms have also recently weighed in on AKRX. Zacks Investment Research upgraded shares of Akorn from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Jefferies Group set a $34.00 price objective on shares of Akorn and gave the stock a “hold” rating in a research report on Sunday, October 29th. Finally, Piper Jaffray Companies set a $34.00 price objective on shares of Akorn and gave the stock a “hold” rating in a research report on Sunday, October 22nd. Three equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. Akorn has an average rating of “Hold” and an average target price of $29.17.
Akorn (AKRX) opened at $31.98 on Monday. Akorn has a 52-week low of $19.67 and a 52-week high of $34.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16. The firm has a market cap of $4,000.00, a P/E ratio of 54.20, a price-to-earnings-growth ratio of 1.66 and a beta of 1.33.
Several large investors have recently modified their holdings of AKRX. State of Alaska Department of Revenue acquired a new stake in shares of Akorn during the 4th quarter valued at $199,000. LMR Partners LLP acquired a new stake in shares of Akorn during the 3rd quarter valued at $200,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Akorn during the 2nd quarter valued at $209,000. Suntrust Banks Inc. acquired a new stake in shares of Akorn during the 2nd quarter valued at $234,000. Finally, Bluefin Trading LLC acquired a new stake in shares of Akorn during the 2nd quarter valued at $268,000. 73.34% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Akorn (AKRX) Upgraded by BidaskClub to Sell” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/07/akorn-akrx-upgraded-by-bidaskclub-to-sell.html.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.